Acute undifferentiated leukemia (AUL) is a subtype of acute leukemias of ambiguous lineage. There is no standard treatment approach for AUL, although acute lymphoblastic leukemia–like regimens for induction therapy have been used. Additional data suggest that AUL may be better treated as acute myeloid leukemia (AML), given their similarities in genetic, cytogenetic, and gene expression patterns. Somatic mutations of IDH1 are found in 7% to 14% of patients with AML; however, the patient in this study was the first patient with IDH1-mutated AUL treated with ivosidenib. In this case, a woman aged 39 years was found to have anemia and thrombocytopenia after presenting to her primary care physician with fatigue, weight loss, and persistent infections. During further workup of the cytopenia, she was diagnosed with AUL and received 7+3 (daunorubicin, 60 mg/m2/d intravenously on days 1–3, and cytarabine, 100 mg/m2 24-hour continuous intravenous infusion on days 1–7) due to the presence of the IDH1 mutation. Bone marrow biopsy performed on day 14 of 7+3 showed persistent disease, and ivosidenib was initiated due to severe HLA alloimmunization (panel-reactive antibody, 100%) and significant bleeding complications. The patient achieved a complete morphologic and molecular remission on ivosidenib monotherapy despite critical bleeding complications during induction. Targeted therapy using ivosidenib may represent an encouraging therapeutic option in patients with AUL and IDH1 mutations. Additional evaluation of ivosidenib in this subgroup of patients with AUL is needed.
Submitted July 31, 2019; accepted for publication October 14, 2019.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Correspondence: Sandipkumar H. Patel, MBBS, Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, A350C Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210. Email: email@example.com
ArberDA, OraziA, HasserjianR, . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405.10.1182/blood-2016-03-64354427069254)| false
LaoZT, DingLW, AnO, . Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Haematologica 2019;104:e200–203.10.3324/haematol.2018.20291130514800)| false
Brito-BabapulleF, PullonH, LaytonDM, . Clinicopathological features of acute undifferentiated leukaemia with a stem cell phenotype. Br J Haematol 1990;76:210–214.209432310.1111/j.1365-2141.1990.tb07873.x)| false
CuneoA, FerrantA, MichauxJL, . Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine cases. Cancer Genet Cytogenet 1996;92:31–36.895686810.1016/S0165-4608(96)00127-6)| false
LiuQF, FanZP, WuMQ,
. Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. Ann Hematol2013;92:679–687.
LiuQF, FanZP, WuMQ, . Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. Ann Hematol 2013;92:679–687.10.1007/s00277-012-1662-423274355)| false
Guru MurthyGS, DhakalI, LeeJY,
. Acute leukemia of ambiguous lineage in elderly patients—analysis of survival using Surveillance Epidemiology and End Results-Medicare database. Clin Lymphoma Myeloma Leuk2017;17:100–107.
Guru MurthyGS, DhakalI, LeeJY, . Acute leukemia of ambiguous lineage in elderly patients—analysis of survival using Surveillance Epidemiology and End Results-Medicare database. Clin Lymphoma Myeloma Leuk 2017;17:100–107.10.1016/j.clml.2016.11.007)| false
DangL, SuSM. Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem 2017;86:305–331.10.1146/annurev-biochem-061516-044732)| false
MarcucciG, MaharryK, WuYZ,
. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol2010;28:2348–2355.
MarcucciG, MaharryK, WuYZ, . IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348–2355.10.1200/JCO.2009.27.3730)| false
NorsworthyKJ, LuoL, HsuV, . FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res 2019;25:3205–3209.10.1158/1078-0432.CCR-18-374930692099)| false